Arthneeti
Latest: Natco Pharma Ltd Q1 FY27 (Apr–Jun 2026) results →This page is Q4 FY26 (Jan–Mar 2026).All Q4 FY26 results →
NP

Natco Pharma Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Natco Pharma Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Price₹882
Market cap₹16.4K Cr
P/E11.6
Updated23 Aug 2026
Read4 min read

Natco Pharma Ltd Q4 FY26 key numbers

Revenue
Earnings expected to settle around INR 700-750 crores in FY '27, driven mostly by base business as no big launches are planned that year.

As stated in Natco Pharma Ltd's Q4 FY26 earnings call transcript · published 10 Jun 2026. Reported figures, not investment advice.

The short version

Earnings expected to settle around INR 700-750 crores in FY '27, driven mostly by base business as no big launches are planned that year. FY '26 earnings expected to settle around INR 700-750 crores, roughly half of FY '25 PAT (INR 1,400 crores) due to dips in certain key product exclusivities.

From Natco Pharma Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Earnings expected to settle around INR 700-750 crores in FY '27, driven mostly by base business as no big launches are planned that year.
  • From FY '28 onwards, projected growth is around 15% to 25% annually based on pipeline and exclusivities.
  • Growth drivers include new product launches in oncology, semaglutide exclusivities, and expansions in Brazil, Canada, and South Africa markets.
  • Subsidiary revenues to grow significantly, with Brazil expected to increase from approx INR 280 crores to INR 550-600 million and Canada growing around 10-15%.
  • Focus on building a more diversified and stable global portfolio to reduce volatility, aiming for base revenue to contribute 70% profit and exclusive products 25-30%.

2 more points from Natco Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Natco Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Natco Pharma is actively pursuing acquisitions to diversify revenue and reduce earnings volatility.
  • The company has been working on expanding globally with investments in Brazil, Canada, South Africa, Indonesia, and the U.S.
  • South Africa investment is expected to take 3-4 years to yield returns; other international operations (Brazil, Canada) are in various stages of profitability.
  • Natco's strategy focuses on building a global company with geographical diversification.
  • Management prefers deploying cash on strategic acquisitions over share buybacks to strengthen core business and global footprint.

2 more points from Natco Pharma Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Natco Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The following relevant points about product launches and pipelines can be noted: - Natco is working on building a pipeline with several exclusives expected to launch between FY '27 and '28, contributing to revenue growth of 15-25%. - Filings and launches planned include semaglutide (launch timing uncertain), ibrutinib, olaparib, carfilzomib, and others with potential exclusivities up to 7-8 years. - Brazil subsidiary expects growth from about INR280 crores to INR55-60 million in earnings this year. - Canada business (~INR229 crores this year) to grow 10-15%, with oncology launches expected in '27-'28.

2 more points from Natco Pharma Ltd's call on order book

Create a free account to keep reading this call

Natco Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Sep 2024Q2 FY25
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26

Q4 FY26 figures are not in this chart yet. Latest shown: Dec 2025 (Q3 FY26). The Q4 FY26 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹647 Cr, net profit ₹151 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Natco Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pha. (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Guj. Themis Bio. (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Natco Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Natco Pharma Ltd Q4 FY26 results?

Earnings expected to settle around INR 700-750 crores in FY '27, driven mostly by base business as no big launches are planned that year. FY '26 earnings expected to settle around INR 700-750 crores, roughly half of FY '25 PAT (INR 1,400 crores) due to dips in certain key product exclusivities.

What is Natco Pharma Ltd share price analysis?

Natco Pharma Ltd currently shows a neutral. The stock trades at a P/E of 11.6 with a market cap of ₹16,434 Cr. Investors should review the full earnings analysis for detailed insights.

Is Natco Pharma Ltd planning capital expenditure?

Natco Pharma is actively pursuing acquisitions to diversify revenue and reduce earnings volatility.

Keep Natco Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.